Bioiberica closed 2009 with a turnover of $152 million and significant growth compared to the previous year. These results indicate that the company is on the right track and heading for a promising future.
As Bioiberica celebrates its 50th anniversary, Luis Solera, CEO reflects on the company’s evolution—from a pioneer in heparin production to a global leader in the biotech industry.